| Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives |
| 3. |
|
Restructuring Charges and Other
Costs Associated with Acquisitions and Cost-Reduction/Productivity
Initiatives
|
We incur significant costs in
connection with acquiring businesses and restructuring and
integrating acquired businesses and in connection with our global
cost-reduction and productivity initiatives. For
example:
| • |
for our cost-reduction and productivity initiatives, we
typically incur costs and charges associated with site closings and
other facility rationalization actions, workforce reductions and
the expansion of shared services, including the development of
global systems; and |
| • |
for our acquisition activity, we typically incur costs
that can include transaction costs, integration costs (such as
expenditures for consulting and the integration of systems and
processes) and restructuring charges, related to employees, assets
and activities that will not continue in the combined
company. |
All of our businesses and functions
can be impacted by these actions, including sales and marketing,
manufacturing and research and development, as well as functions
such as information technology, shared services and corporate
operations. In early February 2011, we announced a new research and
productivity initiative to accelerate our strategies to improve
innovation and overall productivity in R&D by prioritizing
areas with the greatest scientific and commercial promise,
utilizing appropriate risk/return profiles and focusing on areas
with the highest potential to deliver value in the near term and
over time.
The components of costs incurred in
connection with our acquisitions and our
cost-reduction/productivity initiatives follow:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
YEAR ENDED DECEMBER 31,
|
|
|
(MILLIONS OF
DOLLARS) |
|
2011 |
|
|
2010 |
|
|
2009 |
|
|
Transaction costs(a)
|
|
$ |
30 |
|
|
$ |
22 |
|
|
$ |
768 |
|
|
Integration costs(b)
|
|
|
730 |
|
|
|
1,004 |
|
|
|
569 |
|
|
Restructuring charges(c)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Employee termination costs
|
|
|
1,791 |
|
|
|
1,114 |
|
|
|
2,564 |
|
|
Asset impairments
|
|
|
256 |
|
|
|
870 |
|
|
|
159 |
|
|
Other
|
|
|
127 |
|
|
|
191 |
|
|
|
270 |
|
|
Restructuring charges and certain
acquisition-related costs
|
|
|
2,934 |
|
|
|
3,201 |
|
|
|
4,330 |
|
|
Additional
depreciation—asset restructuring, recorded in our
consolidated
statements of income as
follows(d):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of Sales
|
|
|
557 |
|
|
|
527 |
|
|
|
133 |
|
|
Selling, informational and
administrative expenses
|
|
|
75 |
|
|
|
227 |
|
|
|
53 |
|
|
Research and development
expenses
|
|
|
607 |
|
|
|
34 |
|
|
|
55 |
|
|
Total additional
depreciation—asset restructuring
|
|
|
1,239 |
|
|
|
788 |
|
|
|
241 |
|
|
Implementation costs,
recorded in our consolidated statements of income
as follows(e)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
250 |
|
|
|
— |
|
|
|
46 |
|
|
Selling, informational and
administrative expenses
|
|
|
25 |
|
|
|
— |
|
|
|
159 |
|
|
Research and development
expenses
|
|
|
72 |
|
|
|
— |
|
|
|
36 |
|
|
Other
deductions—net
|
|
|
— |
|
|
|
— |
|
|
|
9 |
|
|
Total implementation costs
|
|
|
347 |
|
|
|
— |
|
|
|
250 |
|
|
Total costs associated
with cost-reduction and productivity initiatives and
acquisition activity
|
|
$ |
4,520 |
|
|
$ |
3,989 |
|
|
$ |
4,821 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| (a) |
Transaction costs represent external costs directly related to
acquired businesses and primarily include expenditures for banking,
legal, accounting and other similar services. Substantially all of
the costs incurred in 2009 were fees related to a $22.5 billion
bridge term loan credit agreement entered into with certain
financial institutions on March 12, 2009 to partially fund our
acquisition of Wyeth. The bridge term loan credit agreement was
terminated in June 2009 as a result of our issuance of
approximately $24.0 billion of senior unsecured notes in the first
half of 2009.
|
| (b) |
Integration costs represent external, incremental costs
directly related to integrating acquired businesses, and primarily
include expenditures for consulting and the integration of systems
and processes.
|
| (c) |
From the
beginning of our cost-reduction and productivity initiatives in
2005 through December 31, 2011, Employee termination
costs represent the expected reduction of the workforce by
approximately 57,400 employees, mainly in manufacturing and sales
and research, of which approximately 42,800 employees have been
terminated as of December 31, 2011. Employee termination costs
are generally recorded when the actions are probable and estimable
and include accrued severance benefits, pension and postretirement
benefits, many of which may be paid out during periods after
termination. Asset impairments primarily include charges to
write down property, plant and equipment to fair value.
Other primarily includes costs to exit certain assets and
activities.
|
The restructuring charges
in 2011 are associated with the following:
| |
• |
|
Primary
Care operating segment ($593 million), Specialty Care and Oncology
operating segment ($220 million), Established Products and Emerging
Markets operating segment ($110 million), Animal Health and
Consumer Healthcare operating segment ($51 million), Nutrition
operating segment ($4 million), research and development operations
($489 million), manufacturing operations ($280 million) and
Corporate ($427 million).
|
The restructuring charges
in 2010 are associated with the following:
| |
• |
|
Primary
Care operating segment ($71 million), Specialty Care and Oncology
operating segment ($197 million), Established Products and Emerging
Markets operating segment ($43 million), Animal Health and Consumer
Healthcare operating segment ($46 million), Nutrition operating
segment ($4 million), research and development operations ($292
million), manufacturing operations ($1.1 billion) and Corporate
($455 million).
|
The restructuring charges
in 2009 are associated with the following:
| |
• |
|
Our three
biopharmaceutical operating segments ($1.3 billion), Animal Health
and Consumer Healthcare operating segment ($250 million), Nutrition
operating segment ($4 million income), research and development
operations ($339 million), manufacturing operations ($292 million)
and Corporate ($781 million).
|
| (d) |
Additional depreciation—asset restructuring represents
the impact of changes in the estimated useful lives of assets
involved in restructuring actions.
|
| (e) |
Implementation costs generally represent external, incremental
costs directly related to implementing our non-acquisition-related
cost-reduction and productivity initiatives.
|
|
|
|
|
|
|
|
| The
components of restructuring charges follow: |
|
|
|
|
|
|
|
|
|
COSTS
INCURRED
|
|
ACTIVITY
THROUGH
DECEMBER 31, |
|
ACCRUAL
AS OF
DECEMBER 31,
|
|
(MILLIONS OF
DOLLARS) |
|
2005-2011 |
|
2011(a) |
|
2011(b)
|
|
Employee termination costs
|
|
$10,602 |
|
$ 8,167 |
|
$2,434 |
|
Asset impairments
|
|
2,564 |
|
2,564 |
|
— |
|
Other
|
|
1,022 |
|
931 |
|
92 |
|
Total
|
|
$14,188 |
|
$11,662 |
|
$2,526 |
| |
|
|
|
|
|
|
| (a) |
Includes adjustments for foreign currency
translation.
|
| (b) |
Included
in Other current liabilities ($1.6 billion) and Other
noncurrent liabilities ($928 million).
|
|